HALO - Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth Eyeing Market Expansion | Benzinga
On Wednesday, for the first time, Halozyme Therapeutics Inc (NASDAQ:HALO) provided five-year financial guidance up to 2028.
For 2023, Halozyme expects revenues of $827 million-$832 million versus a consensus of $835.69 million, with Adjusted EPS of $2.77-$2.80 compared to the consensus of $2.74.
For fiscal year 2024, Halozyme forecasts Adjusted EPS of $3.55-$3.90, with revenue guidance of $915 million-$985 million.
Also Read: Roche’s One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe.
In 2028, the company expects these numbers to have grown to revenues of $1.565 billion-$1.69 billion.
HC Wainwright notes a potential upside to guidance from products ...